At CPhI Worldwide, India set out its stall as a leading generics manufacturer and exporter. Hilary Ayshford found out what the country is doing to enhance its prospects still further.
In the global pharmaceutical market, there is no doubt that India is already a major player, particularly where generics are concerned. Over the past five years the Indian pharma market has recorded a compound annual growth rate of 15%, despite the global recession, and more than 70% of patients in 87 countries get their antiretroviral drugs from India.
But far from resting on its laurels, the Indian government has embarked on an ambitious initiative to boost this trade still further until it is second only to the US as the world’s largest pharma exporter.
Brand India Pharma is a significant initiative being led by Pharmaceutical Export Promotion Council (Pharmexcil) and India Brand Equity Foundation (IBEF) under the aegis of the Department of Commerce to highlight the value proposition that Brand India Pharma represents today for the global pharmaceutical industry. A strong contingent of Indian companies, together with representatives from the Department of Commerce and Pharmexcil, used the CPhI Worldwide exhibition in Madrid in October to showcase the strengths of the Indian pharma sector and at the same time, the opportunities available in the Indian pharmaceutical market.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.